New mRNA vaccine takes on Virus-Linked cancers
NCT ID NCT07349836
First seen Jan 25, 2026 · Last updated May 08, 2026 · Updated 15 times
Summary
This early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to train the immune system to recognize and attack virus-infected cancer cells. Researchers will check safety and whether the drug shrinks tumors or slows disease, both alone and combined with a checkpoint inhibitor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.